N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "NextPoint Therapeutics Announc" (14 stories)

Top Headline Story

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors
Lead StoryBusiness Wireworld
Feb 9

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPSG1pdXRUWmJxSTNqMW8zS2hOM3pOMXpDR2xqVkRtZ0ljeEpfekNfbTlwYURkVjgtNnhFeVBpYmZGWnlrTml1RG5mQW5oWWFrbEpSeGJNUGhQSEx6V0g4RFR5ckxlWlQ0WWlSQkd1T1hjMGFaNlRMU2V1OElESDk2Vnl2bk1zTldhTU1nZW0zRFlCR0xMQ1UyOVZ2RWtnM2xCMmVCTlhvcEVneUF6azdjRWkyQmdkTl81cXYyaXRScDlOSElLNmpQWjQxQ0hmb2NTMm0zVDBfMjlJb1R5dlJWbThlaG81SWxpbXc0N0U4dUdDbUJIRXlZRGJMV2xQaFd5YU9iRjRHUG5rOGE1UG9z?oc=5" target="_blank">NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+17m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+17m ago

pope francis

The Myth of St. Francis

Filter stories
500+27m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+27m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "NextPoint Therapeutics Announc"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

13 stories displayed
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
Business Wireworld

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNNjZsWEVwQURxRmNuVktyS0hwa3dLUmwyMWdvQkg2Z1ItTmNLOUFBNmxWVTdvSmhqUmpVdzdCZ3RHcDRXcnZCemVCcmZkR0Nod2Rac1k1aWQwQk1kTl9kUnF1SGRraFk4Y3d6Q3psNUptOEQwQzVxWXM1ZDFxWlZfdWlsdVNmUWk4WTBlX2Vjb0dkaThLVUQyNFVqOFNHUERpZFd2WVB5R0ZsdTRWcDZWLVk0d3ctczh0VzdweUpPWG1qRlVuZFZHcWthd01fS3V0OEJzRlVCdE8xSFZoU01uNWd6VVZwNHpkZzRBRjFYbkxRN0tuemc?oc=5" target="_blank">NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
NextPoint doses first subject with NPX267 to treat solid tumours
Clinical Trials Arenageneral

NextPoint doses first subject with NPX267 to treat solid tumours

<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE5GNE10QTRMQWNqRWM1MlBOYklPUjZZTjlmQ1pVMmQxSUdfWjN6aXVLdktJSDVMcjZZZmFFNzR6Zm5nUkpmSGRqMU45NFdLR0xhMUV4Q0dVNERyMjl3bGlNYkVQN0JOZThLMDkwM1hnX3hmdzZKd1gxeTRuWm8?oc=5" target="_blank">NextPoint doses first subject with NPX267 to treat solid tumours</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb
Pharmaceutical Technologygeneral

FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQOTFsRWR4REMtOERfYl9MR1d0SHlydjNvOW94MVlkal8ybDBlS0l3cU9ZTG11V09zLWstX1Y1UjJiMk5DYVdQVFRZOVZXNFJ0UVBxOHBvOFM4UF9ybXVaYUgxdWVWbEJ5TVRmNWRlYnFWeXlMYUtxZ1c1OGxkdlRENFctYWE5NGtIOHFHekxyUDh1TWhpVlFvNWJmT21fVGJVa2NLU3FhUG1fQ0dVVUE?oc=5" target="_blank">FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
NPX887 being explored in HHLA2+ solid tumors, including RCC
Urology Timesgeneral

NPX887 being explored in HHLA2+ solid tumors, including RCC

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQQkhpUWRCcDVGLWNuVnBSWWpMQWh3cUxYQXdraWp2S1JrR1BGWVdBWDByTmZzdDlsUWtQb1dINTZjMFFUSTZ1cjFsNUNCYVB3bEFOTUlaU1RtQmNaNkdJc1VvNjFzaG15MHZNU2stdFZMY1FHclVOclQyOUFtSlRuRUJpeGRnUW9vMVpTVTA3dUNiTWFmUWc?oc=5" target="_blank">NPX887 being explored in HHLA2+ solid tumors, including RCC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors
BioPharma APACgeneral

NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOV2JzNjBwRkc5aTVkZU8tWDR1bVItNEt3Z3dOWlBqT010Y2dSVWNkcGlYMlJTaThCeml5bTBfMWlBcGRScm9xbGF0dUgwRXBfX19zYWRrMElfaktRVjJBZWhNMnJIS3Z1anlvV3JzelJHX2ZSLW5wbVphd2xaVkd3S0RMVHhBMnBPc1cyM09OWGhYQWRFNjVhTFZMQmhvYmJYQzZpYW1pX2FYbWxRaW9ISW1OdnBGTlk0bjBlcE5IME8yNnJLOU05S2s4dDFweEIwUWpnTGQ1V3VGWktqQ0pSR2V3?oc=5" target="_blank">NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors</a>  <font color="#6f6f6f">BioPharma APAC</font>

Read Full StoryMore like this
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
PR Newswireworld

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPUzl5LTZRc2YtNmhwMmZjUjlYcWVmaVJDNGg3WVdHNndFMTc4Q2xLY2tuY2duRG9FVURuVWhYaF9DcjVMM3FyVnlSbExCS2x4V0ZXMnZDNm1hckR2LVBRb2xTV3NpOVpIYklUX2kzcENRMXJ0VG5Od180MWFBUUFVaDJMZklsdDRKbkRycWhvLXBRTG9Pa3ZfdEtvRTg2M2Vsb1RjT1pQdHJKQTAyaHRVTzNvbVZScjRTOFNaMFRUM0dqdHNhSzFfSUFSQVBRbkw4NWVKb2FaWFNSajd4cFRkZGNXNVVLdzZJbExXTGVBYXktOXk5Q3JBa2lxX2dqUmM?oc=5" target="_blank">Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Eisai's U.S. CEO hired to lead Cambridge cancer biotech
The Business Journalstech

Eisai's U.S. CEO hired to lead Cambridge cancer biotech

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9OVDUxc01ZbWx3dFBuZTk0WjVtUGl6ZG9IaTBST3Bld3k3cm4zSkhPakdDeVM3d0daekZqSlE4UmxLNENNZXVlYzBLZnBnTTZQRzI4cVhlV2tDQ1h4R3E5VE14Q1JSc0lhM3hDeDVwN2dyUExKdmV2MzA0NmI1Zw?oc=5" target="_blank">Eisai's U.S. CEO hired to lead Cambridge cancer biotech</a>  <font color="#6f6f6f">The Business Journals</font>

Read Full StoryMore like this
Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint
Fierce Biotechtech

Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNMWNGM1c3MVVPQ01KajlScVVMYnBxa25hRDZ0U2FQQnhJLUlxUWRrcC1yWm1sTXF1SWZXN3hLNi1uZjRodUdEV18tZ094UEdlci1PUHVWVFFZTEJxUW02NTY0WTRtYy11VWNya0RiQ3hpYVdqSV8zVzdKOFFZTWNIbUZJS0VzNTVZMTVZY2NxZHJDcG5zaTRwaTBoNkd4cVFaNUFiUHdB?oc=5" target="_blank">Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset
Endpoints Newsgeneral

Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOUXBZM2tzRGpvUlhmakFQekh4aFVac1p2aWlTVmFPcVhZdlQxYWp4N2MzaUhMWHZsTmZzSDJJQ09xanZHM3YwTmhkb3lfdUJrS2QyUGwzLWhoQU9xZkg1YnVGVnUtQzNZbDU0SUFIalVWOVlUQUtEX08tMnpiRlJERDkxZmhEUzh2TG8xSVBWcnVrZnZzSGx6aUdCQ21tTmlwb3VuSXhiaw?oc=5" target="_blank">Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
NEXTPOINT FINANCIAL ANNOUNCES FORBEARANCE AGREEMENTS WITH LENDERS
PR Newswire Canadaworld

NEXTPOINT FINANCIAL ANNOUNCES FORBEARANCE AGREEMENTS WITH LENDERS

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPYmxCYTNBeGNtSzZKaXBLZ2N1UHZmdWx2dmdKWnNSdHlxM0JBRUhtZkdsUUJBVDA0WHNXSkpoUGY3eXE2QUI4SzZKR1NFdWxzM2pOTjdWUHh4M0JKNlNmQ1J4VHFaaHVhUDJ4SmhFbXNodFBIUTl3bUpicnlFdENZbjFRdWdHcmJMZVNzV0ZyZWRPZTNmQVNlbHZzYkJoSlhyaGQ5cU5MdENBem52T0JLekZJUWI1SnVTQWc?oc=5" target="_blank">NEXTPOINT FINANCIAL ANNOUNCES FORBEARANCE AGREEMENTS WITH LENDERS</a>  <font color="#6f6f6f">PR Newswire Canada</font>

Read Full StoryMore like this
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
Business Wiregeneral

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxORlVKeklUSDJuTWo2WmtSNWxSeE1tdzFaVUZfYU5pS1JBNkJhT0laMmFQdDlHMHBDb2REdEw1cGJrNk1OU1Z1RlRHaV9hVFZRU2tQcWk1bVRWV0tndHBQWkcxZDVPY1hTWTNRaU82OWNtWHJEZ2pCTUlnNVEwYTJwQXV4aERBeXVwTTFUOGJ4cWJtX05aZENwaUdRdW5qOUN1VlZ6aFNETDVKajZCSlFUQ2JRMEltWkRwT3ZKN1hlXzdXVDVUektqRGx5Wm9uR0ZjR2dwMng1aUNKNXUzZUI3bllKM1YwZmtRZW1oWkRjRUhCUWVLZnYwTUlsbkhnUURYSEVPV00xOFVCN3BQeFI4a0w4LXRNTDVIbEFkOXNGQVFiazltSDlCY0Jwd0l1T2Y4LVE?oc=5" target="_blank">NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M
Fierce Biotechtech

Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxONjI2THYyOU9rbVhMMDRXU1JWNF9zcjRaT0R2TXR3SU5iQTktN1FYTlY1YzQzSkstRVFGZGxsOWg1RThVWENZTkRmemYyMEhBZzZFWUJZZ2h1YVJzN1NKaVpBSmMzWEU0TXlUbVhaZ0JtLTZDZmxiM1JEU1dBcU1PMg?oc=5" target="_blank">Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee
Business Wireworld

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQQ0xfWFd2MlFuSk9hazVfUWc2X3ltZGRvN0VEUlZwM1VfMDRVSGJMVmh6M2JtLXJpT1paamEtVzhLa0J5MXVZQ2t1MVluR0psMWNXZlhDQmpQenl2dlRXRmd1aVBTVnVlZHNtQ2JzNTJ3NW5KcFhObzFaSk5yVEZ4QjNsWHdzUUhEbFk0eG1IQ1dOeFFZOUYzMElGc2hVNWNtU0NvRm5LcW0tQW1FZ05QX3A5Vl9FazVsUEFjUllMTFJWVGJ4aTlKVGkxTGpWN3prd1RJMjBTRzNDOVdnTVM5ZF9DWQ?oc=5" target="_blank">MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
"NextPoint Therapeutics Announc" — Live Google News Trends & Headlines